Jyseleca failure in Crohn's will shift pipeline attention to novel target

Belgian biotech Galapagos’ (Euronext: GLPG) suffered a disappoint earlier this month, when its already commercialized JAK inhibitor Jyseleca (filgotinib) fell short in the induction cohorts of a Phase III Crohn's disease (CD) trial.

Responding to the development, analytics firm GlobalData noted that the results are expected to shift the attention of the late-stage CD pipeline from established drug classes such as the Janus kinase or the interleukin-23 (IL-23) inhibitors towards developing novel CD therapeutic targets.

Among the 19 assets in late-stage clinical development, only six (ozanimod, etrasimod, obefazimod, TEV-48574, PRA-023, PF-0648065) are being pursued as first-in-class for novel therapeutic targets in CD.